“…In some countries, triple therapy with a proton-pump inhibitor, amoxicillin, and clarithromycin is still the best option, and on the other hand, countries with clarithromycin resistance >20%, bismuth-containing quadruple therapy, non-bismuth sequential, or concomitant therapies may be the preferred option [29]. Studies had revealed higher prevalence of H. pylori positive than H. pylori negative among Iraqi population, and in dyspeptic patients, H. pylori prevalence was approximately 74-77% [30,31].…”